论文部分内容阅读
[目的]观察调强放射治疗联合紫杉醇、顺铂化疗治疗食管癌的临床疗效与不良反应。[方法]37例经病理证实的食管癌患者行调强放射治疗,放疗的第1d联合紫杉醇、顺铂同步化疗。随访观察近远期疗效。[结果]全组完全缓解率81.1%,部分缓解率16.2%,总有效率为97.3%。中位生存时间为23.3个月,1、2、3年局部控制率和生存率分别为86.5%、48.6%、35.1%和86.5%、46.0%、29.7%。[结论]调强放射治疗联合紫杉醇顺铂化疗治疗食管癌局部控制率和生存率较高。
[Objective] To observe the clinical efficacy and adverse reactions of intensity modulated radiation therapy combined with paclitaxel and cisplatin in the treatment of esophageal cancer. [Method] Thirty-seven patients with esophageal cancer confirmed by pathology were treated with intensity-modulated radiation therapy and the first day of radiotherapy combined with paclitaxel and cisplatin. Follow-up observation of long-term efficacy. [Results] The complete remission rate was 81.1%, the partial remission rate was 16.2% and the total effective rate was 97.3%. The median survival time was 23.3 months. The local control rates and survival rates at 1, 2 and 3 years were 86.5%, 48.6%, 35.1% and 86.5%, 46.0% and 29.7%, respectively. [Conclusion] IMRT and paclitaxel plus cisplatin chemotherapy have higher local control rate and survival rate in esophageal cancer.